Startup BrachyDOSE to Use €0.5 Million Investment to Advance Cancer Treatment Technology
- viktorijatrimbel6
- 11 hours ago
- 4 min read
Medical technology startup BrachyDOSE has secured an investment of €554,000 to test its radiation measurement technology in a clinical environment. The funding round was led by venture capital fund Coinvest Capital, with participation from BSV Ventures and business angel networks LitBAN and EstBAN.
The investment will support BrachyDOSE in completing the CE and Medical Device Regulation (MDR) certification process required to bring its device to market. CE marking confirms that a product complies with European Union health, safety, and environmental protection standards, while MDR certification ensures adherence to regulations governing the design, manufacture, and distribution of medical devices within the EU.
“We are grateful to the venture funds and angel investors who have supported us on our journey. This investment is a major boost that gives the BrachyDOSE team the opportunity to pursue our goal of helping cancer patients avoid the side effects of radiotherapy, while enabling hospitals and doctors to significantly improve the quality of cancer treatment,” said Neringa Šeperienė, founder and CEO of BrachyDOSE. “Once we obtain CE/MDR certification, we will be able to offer our product to both Lithuanian and international markets.”
“Lithuania is recognised as one of the leading centres for training oncology specialists and scientists. We have modern infrastructure and decades of experience, yet Lithuanian-developed tools and technologies remain limited in this highly dynamic field. BrachyDOSE stands out for its versatility and broad applicability – the technology can be used in any oncology hospital worldwide. This is encouraging news for investors, but more importantly, it may be good news for cancer patients and oncology professionals alike,” said Viktorija Trimbel, Managing Director of Coinvest Capital.
Coinvest Capital contributed €300,000 as the lead investor in this round.
Sandra Golbreich, Partner at BSV Ventures, commented: “Radiotherapy is a cornerstone of cancer treatment, but until now, doctors have had to rely on approximations of dose delivery, which can lead to unwanted side effects for patients. BrachyDOSE’s data-driven solution introduces a new level of precision that can significantly reduce these side effects. It’s a breakthrough for both patients and clinicians. As early supporters of BrachyDOSE, we’ve seen firsthand Neringa and her team’s [1] unique expertise and strong commitment to improving patient outcomes. We are proud to continue supporting them and are excited to co-lead this round to help bring such an innovative solution to hospitals worldwide.”
BrachyDOSE is a patient-centric, data-driven measurement tool that helps doctors’ to prevent up to 100% of treatment-caused injuries in radiotherapy procedures. The solution is hardware and software combined.
The hardware includes a sensor and a scanner used to retrieve the data, while the software uses an injury prediction algorithm to provide decision support for a doctor. BrachyDOSE enables to save hospital costs, makes radiotherapy more efficient and most importantly helps cancer patients to recover faster.
The company has already collaborated with the National Cancer Centre of Vilnius University Hospital Santaros Clinics and the Oncology Hospital of the Lithuanian University of Health Sciences.
“Our approach is based on the belief that knowledge only creates value when it is applied. That’s why we want to share our competences and knowledge – to make the work of hospitals and doctors easier. Our team includes experts in medical device engineering, data analytics, and medical physics. We are joined by medical oncologists who work directly with patients in hospitals, experts in quality management systems and CE certification, as well as a medical device salesperson,” said N. Šeperienė.
Šeperienė holds degrees in applied physics and medical physics and earned a PhD in materials engineering from Kaunas University of Technology.
Thanks for pooling this deal together to Sandra Golbreich, Jana Budkovskaja, Roberta Rudokiene, Daiva Rakauskaite, CFA and all Coinvest Capital team as well as our great legal advisors from TEGOS Legal and Dalia Tamašauskaitė-Žilienė
About Coinvest Capital
Coinvest Capital is an early-stage venture capital fund established by the national development bank ILTE. The fund invests public funds of EU and Republic of Lithuania, alongside private investors, in promising European start-ups that create value for Lithuania. Since the beginning of its operations, the Fund, together with its partners, has invested in 48 startups and exited 6 investments. The total venture capital deployed alongside private partners amounts to more than €53.2 million, of which €23.1 million was contributed by Coinvest Capital. Under the profit-sharing model, private co-investors have contributed €12.5 million, while an additional €17.6 million has been invested under the pari-passu model. The Fund offers a globally unique profit-sharing program, capping its annual return on investments at 4 to 8 percent. In the event of a successful exit, any return exceeding this cap is allocated to accredited private co-investors. Out of the €44.3 million in committed capital entrusted to the Fund, €14.9 million remains available for new investments following this transaction.
About BSV Ventures
BSV Ventures is a 15 Million venture capital fund specialising in Deep Tech, Life Science, and Dual-Use investments with a focus on breakthrough critical technologies and a strong commitment to the Baltic and Nordic regions. To enable the realisation of early ideas, BSV Ventures organises specialised incubation and acceleration programs for scientists and engineers. The fund's major investors are the national development bank ILTE and the NATO Innovation Fund.
More information: